Strides Shasun gains after acquisition

Strides Shasun rose 1.06% to Rs 1,091.95 at 10:14 IST on BSE after the company said its UK-based subsidiary will acquire PediaCare brand from Sweden's Moberg Pharma for $5 million plus inventory value at closing.

The announcement was made after market hours on Friday, 25 November 2016.

Meanwhile, the BSE Sensex was down 67.76 points, or 0.26%, to 26,248.58.

On BSE, so far 9,778 shares were traded in the counter, compared with average daily volume of 67,539 shares in the past one quarter. The stock hit a high of Rs 1,100 and a low of Rs 1,077 so far during the day. The stock hit a 52-week high of Rs 1,400 on 10 December 2015. The stock hit a 52-week low of Rs 848 on 29 February 2016. The stock had outperformed the market over the past 30 days till 25 November 2016, rising 14.98% compared with the 5.73% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 13.44% as against Sensex's 5.28% decline.

The mid-cap company has equity capital of Rs 89.37 crore. Face value per share is Rs 10.

Strides Shasun announced that its wholly-owned subsidiary Strides Arcolab International, UK has entered into an agreement with Moberg Pharma, Sweden to acquire the 'PediaCare' brand for a total consideration of $5 million plus inventory value at closing.

PediaCare is an established paediatric cough, cold and allergy brand with annual sales of approximately $6 million. PediaCare will form an important part of Strides expanding consumer health care portfolio and brings with it expertise in the paediatric segment as well as a strong brand name with global potential.

Strides Shasun's consolidated net profit rose 106.90% to Rs 74.09 crore on 36.26% rise in net sales to Rs 922.17 crore in Q2 September 2016 over Q2 September 2015.

Strides Shasun is a vertically integrated global pharmaceutical company headquartered in Bangalore.

Powered by Capital Market - Live News